The latest biotech news

multiple sclerosis zinbryta daclizumab biogen abbvie

News and Trends 6 Jul 2016

Newly Approved therapy reduces frequency of Multiple Sclerosis relapses by 54%

Biogen and AbbVie have been granted EU marketing authorization for Zinbryta (daclizumab), to treat adult patients with relapsing forms of multiple sclerosis. Relapse frequency per year was shown to be reduced by up to 45% against other treatments, and 54% against placebo. Biogen is trying to emphasise the need for choice of treatments for MS, as the […]

July 6, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 6 Jul 2016

This company ensures quality DNA suitable for Clinical applications from demanding Human body fluid Samples

For today’s sensitive clinical genetic testing applications, making a fast and affordable isolation of high-quality nucleic acids from whole blood or plasma samples is a key bottleneck. But hey, here is a solution! Nucleic acid quantity and purity is crucial to perform the best NGS (Next Generation Sequencing), as well as other downstream processes like chip-based assays. […]

July 6, 2016 - 4 minutesmins - By Jerome Topsent

tigenix takeda stem cell therapy crohns fistula

News and Trends 6 Jul 2016

Takeda snatches up Belgian Cell therapy for Crohn’s Disease

TiGenix is licensing the rights for its cell therapy which is under EMA review and is meant to treat a serious complication of Crohn’s disease. This worldwide exclusivity deal (with exception to the US) could be worth up to €380M. Back in 2009, Leuven-based TiGenix was the first to launch at cell-based product (ChondroCellect) on the European market. […]

July 6, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 6 Jul 2016

June was a Tough Month for European Biotech… #Fail

Abivax, Celyad, Circassia and Genticel – these are all European Biotechs that took a hit after failing key clinical trials in June. How are they doing now? Four different public Biotechs suffered setbacks in some of their advanced clinical trials. And, as always, the words ‘failed to meet primary endpoint‘ weren’t very popular with investors… […]

July 6, 2016 - 3 minutesmins - By Denise Neves Gameiro

biogeneration capital ventures finance money fund biotech medtech

News and Trends 5 Jul 2016

The Fund behind the ‘Biggest Private Exit Ever’ to Raise another €50M

BioGeneration Ventures has had its first close of a new venture capital fund, ‘BioGeneration Capital Fund III’, for novel diagnostic, medtech and therapeutic biotechs in Europe. BioGeneration Ventures (BGV) is based in Naarden (Netherlands) and manages funds investing in Netherlands, Belgium and Germany. Some of its biotech porfolio companies have included Dezima Pharma (acquired by Amgen from […]

July 5, 2016 - 2 minutesmins - By Dani Bancroft

deskgen desktop genetics biotech labiotech refresh crispr

News and Trends 5 Jul 2016

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

The problem with CRISPR, is that not many people are actually experts in the field, and there are only a select few who worked on it pre-2013. So how did this UK Startup make a big name for itself in field of the ‘Biotech Breakthrough of the Century’? Desktop Genetics is a startup founded in 2012 by three […]

July 5, 2016 - 4 minutesmins - By Dani Bancroft

cinfa amgen biosimilar biotech neutropenia chemotherapy

News and Trends 5 Jul 2016

Spanish Biotech gets New Milestone in Biosimilar Race with Amgen

The Spanish Cinfa Biotech’s race to compete with Amgen’s blockbuster for Chemotherapy-induced Neutropenia continues: the Neulasta biosimilar passes Phase I trials. Neulasta (pegfilgrastim) is a slightly longer acting version of Amgen’s other blockbuster Neupogen (the template for the first ever US approved biosimilar – from Novartis), the combined sales of which account for over 30% of Amgen’s income. […]

July 5, 2016 - 2 minutesmins - By Dani Bancroft

leo pharma astrazeneca dermatology biologics

News and Trends 4 Jul 2016

Danish Pharma enters in the Biologics arena with Antibody Buy-out

Leo Pharma is acquiring rights to two of AstraZeneca‘s candidates. The targeted indications are atopic dermatitis and psoriasis – autoimmune conditions getting more and more attention. Based near Copenhagen (Denmark), Leo Pharma specializes in dermatological therapies – particularly topical treatments. The company is not shy about its acquisitions, having entered a €675M deal to buy Japanese […]

July 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

morphosys thrombosis phaseI novartis hucal

News and Trends 4 Jul 2016

Novartis delivers German Biotech’s 12th Antibody to Clinics

MorphoSys keeps up its impressive productivity in feeding pipelines. Its 12th antibody in its Novartis collaboration has just reached clinical development. After presenting results for two of its wholly-owned candidates at ASCO 2016 (you can get an insider look into ASCO from the team), MorphoSys is receiving good news on the collaborations’ front. One of the […]

July 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

uk biohackathon cambridge cutec 2016 biohacking alpha brick

News and Trends 4 Jul 2016

What kind of Startups were born at the UK’s First Biohackathon?

Organised by the University of Cambridge Technology and Enterprise Club (a catchy ‘CUTEC’ for short), the Biohackathon was the first of its kind organised in the UK… With SynBio veterans such as Bento Bio (inventors of the ‘Lunch box sized Laboratory’ for hackers, schools and DIY enthusiasts), Synthace (which invented Antha – ‘the programming language of […]

July 4, 2016 - 5 minutesmins - By Dani Bancroft

abivax ceo ehrlich interview hiv hepatitis

News and Trends 4 Jul 2016

“We have one of the World’s Most Advanced Functional HIV Cures under development”

Abivax has recently announced that it’s likely that its most advanced program in hepatitis B will fail its Phase III trials. That’s really bad news for the company, and stocks have plummeted by around 50%. But what does this really mean for the future of Abivax? To find out, I had a chat with the company’s CEO Hartmut […]

July 4, 2016 - 5 minutesmins - By Denise Neves Gameiro

kathy high bioart biomedical research blood rats

News and Trends 2 Jul 2016

Blood Wars and Celebrating the Unsung Rats of Science with #BioArt

Kathy High is an American artist exploring the areas of technology, science, speculative fiction and art. She does this with installations and workshops – including one where the audience’s blood fights each other. Kathy High studied fine arts, English literature, video and photography at New York. On top of having a lot of well-known work in […]

July 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Newly Approved therapy reduces frequency of Multiple Sclerosis relapses by 54%

This company ensures quality DNA suitable for Clinical applications from demanding Human body fluid Samples

Takeda snatches up Belgian Cell therapy for Crohn’s Disease

June was a Tough Month for European Biotech… #Fail

The Fund behind the ‘Biggest Private Exit Ever’ to Raise another €50M

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

Spanish Biotech gets New Milestone in Biosimilar Race with Amgen

Danish Pharma enters in the Biologics arena with Antibody Buy-out

Novartis delivers German Biotech’s 12th Antibody to Clinics

What kind of Startups were born at the UK’s First Biohackathon?

“We have one of the World’s Most Advanced Functional HIV Cures under development”

Blood Wars and Celebrating the Unsung Rats of Science with #BioArt

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!